{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T05:31:01Z","timestamp":1792215061482,"version":"4.4.0"},"reference-count":54,"publisher":"American Society for Microbiology","issue":"3","license":[{"start":{"date-parts":[[2005,3,1]],"date-time":"2005-03-01T00:00:00Z","timestamp":1109635200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2005,3]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    A promising approach to improving outcomes in patients with cryptococcal meningitis is to use adjunctive passive immunotherapy with a monoclonal antibody (MAb) directed against the capsular polysaccharide of\n                    <jats:italic>Cryptococcus neoformans<\/jats:italic>\n                    . This is the first application of MAb therapy for the treatment of a fungal disease in humans. We determined the safety and maximum tolerated dose of the murine anticryptococcal MAb 18B7 in a phase I dose-escalation study. The subjects were human immunodeficiency virus-infected patients who had been successfully treated for cryptococcal meningitis. Six dosing cohorts received MAb 18B7 at 0.01 to 2 mg\/kg of body weight as a single infusion. Three patients each received 0.01, 0.05, 0.2, and 0.5 mg of MAb 18B7 per kg without significant adverse events. Four of the subjects who received the 1-mg\/kg dose had mild study drug-associated toxicity, including transient nausea, vomiting, back pain, and urticarial rash. Two of the subjects who received 2 mg\/kg developed drug-associated mild to moderate nausea, vomiting, chills, and myalgias. One of the subjects who received 2 mg\/kg developed intracranial hypertension 10 weeks after MAb 18B7 administration. Serum cryptococcal antigen titers in the cohorts receiving doses of 1 and 2 mg\/kg declined by a median of twofold at 1 week and a median of threefold at 2 weeks postinfusion, but the titers subsequently returned toward the baseline values by week 12. The half-life of MAb 18B7 in serum was approximately 53 h, while the MAb was undetectable in the cerebrospinal fluid of all patients. These data support the continued investigation of MAb 18B7 at a maximum single dose of 1.0 mg\/kg.\n                  <\/jats:p>","DOI":"10.1128\/aac.49.3.952-958.2005","type":"journal-article","created":{"date-parts":[[2005,2,23]],"date-time":"2005-02-23T17:51:53Z","timestamp":1109181113000},"page":"952-958","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":213,"title":["Phase I Evaluation of the Safety and Pharmacokinetics of Murine-Derived Anticryptococcal Antibody 18B7 in Subjects with Treated Cryptococcal Meningitis"],"prefix":"10.1128","volume":"49","author":[{"given":"Robert A.","family":"Larsen","sequence":"first","affiliation":[{"name":"University of Southern California, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter G.","family":"Pappas","sequence":"additional","affiliation":[{"name":"University of Alabama at Birmingham, Birmingham, Alabama"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Perfect","sequence":"additional","affiliation":[{"name":"Duke University Medical Center, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith A.","family":"Aberg","sequence":"additional","affiliation":[{"name":"Washington University School of Medicine, St. Louis, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arturo","family":"Casadevall","sequence":"additional","affiliation":[{"name":"Albert Einstein College of Medicine, Bronx, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gretchen A.","family":"Cloud","sequence":"additional","affiliation":[{"name":"University of Alabama at Birmingham, Birmingham, Alabama"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"James","sequence":"additional","affiliation":[{"name":"Rho Federal Systems Division, Inc., Chapel Hill, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Filler","sequence":"additional","affiliation":[{"name":"Harbor-UCLA Research and Education Institute, Torrance, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William E.","family":"Dismukes","sequence":"additional","affiliation":[{"name":"University of Alabama at Birmingham, Birmingham, Alabama"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197907193010303"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.36.3.690"},{"key":"e_1_3_2_4_2","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1080\/02681219680000041","volume":"34","year":"1996","unstructured":"Blackstock, R. 1996. Cryptococcal capsular polysaccharide utilizes an antigen-presenting cell to induce a T-suppressor cell to secrete TsF. J. Med. Vet. Mycol.34:19-30.","journal-title":"J. Med. Vet. Mycol."},{"key":"e_1_3_2_5_2","unstructured":"Bourne D. 1995. Mathematical modeling of pharmacokinetic data. Technomic Publishing Company Inc. Lancaster Pa."},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.6.1437"},{"key":"e_1_3_2_7_2","unstructured":"Division of AIDS National Institute of Allergy and Infectious Diseases. 1997. Serious adverse event reference manual. National Institute of Allergy and Infectious Diseases Rockville Md."},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/iai.63.7.2632-2644.1995"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI118466"},{"key":"e_1_3_2_10_2","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1093\/infdis\/163.5.1114","volume":"163","year":"1991","unstructured":"Dromer, F., and J. Charreire. 1991. Improved amphotericin B activity by a monoclonal anti-Cryptococcus neoformans antibody: study during murine cryptococcosis and mechanisms of action. J. Infect. Dis.163:1114-1120.","journal-title":"J. Infect. Dis."},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/iai.55.3.749-752.1987"},{"key":"e_1_3_2_12_2","doi-asserted-by":"crossref","first-page":"790","DOI":"10.4049\/jimmunol.158.2.790","volume":"158","year":"1997","unstructured":"Feldmesser, M., and A. Casadevall. 1997. Effect of serum IgG1 to Cryptococcus neoformans glucuronoxylomannan on murine pulmonary infection. J. Immunol.158:790-799.","journal-title":"J. Immunol."},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/37.3.617"},{"key":"e_1_3_2_14_2","unstructured":"Gibaldi M. 1991. Biopharmaceutics and clinical pharmcokinetics 4th ed. Lea & Febiger Malvern Pa."},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/iai.63.9.3448-3453.1995"},{"key":"e_1_3_2_16_2","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1093\/clinids\/21.6.1477","volume":"21","year":"1995","unstructured":"Gordon, M. A., and A. Casadevall. 1995. Serum therapy for cryptococcal meningitis. Clin. Infect. Dis.21:1477-1479.","journal-title":"Clin. Infect. Dis."},{"key":"e_1_3_2_17_2","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/infdis\/114.4.373","volume":"114","year":"1964","unstructured":"Gordon, M. A., and E. Lapa. 1964. Serum protein enhancement of antibiotic therapy in cryptococcosis. J. Infect. Dis.114:373-378.","journal-title":"J. Infect. Dis."},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1080\/00362178185380411"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1086\/514068"},{"key":"e_1_3_2_20_2","first-page":"1","volume":"46","year":"1964","unstructured":"Hirano, A., H. M. Zimmerman, and S. Sevine. 1964. The fine structure of cerebral fluid accumulation. III. Extracellular spread of cryptococcal polysaccharides in the acute stage. Am. J. Pathol.46:1-19.","journal-title":"Am. J. Pathol."},{"key":"e_1_3_2_21_2","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1001\/archneur.1964.00460240064009","volume":"11","year":"1964","unstructured":"Hirano, A., H. M. Zimmerman, and S. Sevine. 1964. Fine structure of cerebral fluid accumulation. V. Transfer of fluid from extracellular compartments in acute phase of cryptococcal polysaccharide lesions. Arch. Neurol.11:632-641.","journal-title":"Arch. Neurol."},{"key":"e_1_3_2_22_2","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1001\/archneur.1965.00460260079009","volume":"12","year":"1965","unstructured":"Hirano, A., H. M. Zimmerman, and S. Sevine. 1965. Fine structure of cerebral fluid accumulation. VI. Intracellular accumulation of fluid and cryptococcal polysaccharide in oligodendria. Arch. Neurol.12:189-196.","journal-title":"Arch. Neurol."},{"key":"e_1_3_2_23_2","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1097\/00005072-196507000-00002","volume":"24","year":"1965","unstructured":"Hirano, A., H. M. Zimmerman, and S. Sevine. 1965. The fine structure of cerebral fluid accumulation. VII. Reactions of astrocytes to cryptococcal polysaccharide implantation. J. Neuropathol. Exp. Neurol.24:386-396.","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"e_1_3_2_24_2","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1089\/hyb.1989.8.231","volume":"8","year":"1989","unstructured":"Khazaeli, M. B. 1989. Quantitation of mouse monoclonal antibody and human anti-mouse antibody response in serum of patients. Hybridoma8:231-239.","journal-title":"Hybridoma"},{"key":"e_1_3_2_25_2","first-page":"42","volume":"15","year":"1994","unstructured":"Khazaeli, M. B., R. M. Conry, and A. F. LoBuglio. 1994. Human immune response to monoclonal antibodies. J. Immunol.15:42-53.","journal-title":"J. Immunol."},{"key":"e_1_3_2_26_2","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.4049\/jimmunol.129.4.1675","volume":"129","year":"1982","unstructured":"Kozel, T. R., and E. C. Gotschlich. 1982. The capsule of Cryptococcus neoformans passively inhibits phagocytosis of the yeast by macrophages. J. Immunol.129:1675-1680.","journal-title":"J. Immunol."},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/19.4.741"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-113-3-183"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/0165-5728(95)00097-L"},{"key":"e_1_3_2_30_2","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1086\/314946","volume":"180","year":"1999","unstructured":"Lendvai, N., and A. Casadevall. 1999. Monoclonal antibody-mediated toxicity in Cryptococcus neoformans infection: mechanism and relationship to antibody isotype. J. Infect. Dis.180:791-801.","journal-title":"J. Infect. Dis."},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.164.8.4367"},{"key":"e_1_3_2_32_2","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.4049\/jimmunol.120.5.1686","volume":"120","unstructured":"Macher, A. M., J. E. Bennett, J. E. Gadek, and M. M. Frank. Complement depletion in cryptococcal sepsis. J. Immunol.120:1686-1690.","journal-title":"J. Immunol."},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.42.6.2786-2788.2004"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.169.3.1379"},{"key":"e_1_3_2_35_2","unstructured":"Milefchik E. M. Leal R. Haubrich S. Bozzette J. Tilles J. Leedom J. A. McCutchan and R. A. Larsen. 1997. A phase II dose escalation trial of high dose fluconazole with and without flucytosine for AIDS associated cryptococcal meningitis. Program Abstr. 4th Conf. Retrovir. Opportunistic Infect."},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-199904160-00005"},{"key":"e_1_3_2_37_2","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1084\/jem.177.4.1105","volume":"177","unstructured":"Mukherjee, J., A. Casadevall, and M. D. Scharff. Molecular characterization of the humoral responses to Cryptococcus neoformans infection and glucuronoxylomannan-tetanus toxoid conjugate immunization. J. Exp. Med.177:1105-1116.","journal-title":"J. Exp. Med."},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.39.7.1398"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.90.8.3636"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1128\/iai.60.11.4534-4541.1992"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.38.3.580"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/173.5.1222"},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.1128\/iai.63.2.573-579.1995"},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.1128\/iai.62.3.1079-1088.1994"},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.1128\/iai.5.6.896-901.1972"},{"key":"e_1_3_2_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(92)90142-P"},{"key":"e_1_3_2_47_2","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1089\/aid.1994.10.1079","volume":"10","year":"1994","unstructured":"Pettoello-Mantovani, M., A. Casadevall, P. Smarnworawong, and H. Goldstein. 1994. Enhancement of HIV type 1 infectivity in vitro by capsular polysaccharide of Cryptococcus neoformans and Haemophilus influenzae. AIDS Res. Hum. Retrovir.10:1079-1087.","journal-title":"AIDS Res. Hum. Retrovir."},{"key":"e_1_3_2_48_2","doi-asserted-by":"publisher","DOI":"10.1128\/iai.64.8.2897-2903.1996"},{"key":"e_1_3_2_49_2","doi-asserted-by":"publisher","DOI":"10.1086\/515074"},{"key":"e_1_3_2_50_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199201093260202"},{"key":"e_1_3_2_51_2","doi-asserted-by":"publisher","DOI":"10.1128\/iai.65.5.1800-1807.1997"},{"key":"e_1_3_2_52_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199707033370103"},{"key":"e_1_3_2_53_2","doi-asserted-by":"publisher","DOI":"10.1080\/mmy.38.6.407.417"},{"key":"e_1_3_2_54_2","doi-asserted-by":"publisher","DOI":"10.1128\/iai.64.7.2846-2849.1996"},{"key":"e_1_3_2_55_2","doi-asserted-by":"publisher","DOI":"10.1128\/iai.63.8.2919-2923.1995"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.49.3.952-958.2005","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.49.3.952-958.2005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,2]],"date-time":"2023-05-02T04:54:56Z","timestamp":1683003296000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.49.3.952-958.2005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,3]]},"references-count":54,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2005,3]]}},"alternative-id":["10.1128\/AAC.49.3.952-958.2005"],"URL":"https:\/\/doi.org\/10.1128\/aac.49.3.952-958.2005","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,3]]},"assertion":[{"value":"2004-06-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2004-11-21","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2005-03-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}